Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 2/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
| ▸ | SCN1A | P35498 | 2/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8801584 | 0.91 | RECQL (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL11479510 | 0.88 | F2 (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL30442076 | 0.83 | CA2 (0.62) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL10994471 | 0.83 | CA1 (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL3698223 | 0.83 | HCRTR1 (0.58) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL8224014 | 0.83 | F2 (0.60) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL2371351 | 0.83 | CA1 (0.57) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL419323 | 0.83 | CA2 (0.62) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL11334125 | 0.82 | HTR6 (0.51) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL3577992 | 0.80 | NSD2 (0.65) | CA1CA2CA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257539-B1 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| US-6531478-B2 | For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders | KORDIK CHERYL P (US) | 2003-03-11 | — | — | US | claimed |
| EP-1257539-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | KORDIK CHERYL P (US) | 2002-05-30 | — | — | US | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2001062737-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| US-11711934-B2 | Metal amides for use as HIL for an organic light-emitting diode (OLED) | NOVALED GMBH (DE) | 2023-07-25 | — | — | US | disclosed |
| EP-4084108-A1 | METAL AMIDES FOR USE AS HIL FOR AN ORGANIC LIGHT-EMITTING DIODE (OLED) | Novaled GmbH (DE) | 2022-11-02 | — | — | EP | disclosed |
| EP-3338313-B1 | METAL AMIDES FOR USE AS HOLE INJECTION LAYER FOR AN ORGANIC LIGHT-EMITTING DIODE (OLED) | NOVALED GMBH (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3338314-B1 | TRIARYL AMINE THICK LAYER DOPED WITH METAL AMIDES FOR USE AS HOLE INJECTION LAYER FOR AN ORGANIC LIGHT-EMITTING DIODE (OLED) | NOVALED GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3133664-A1 | TRIARYL AMINE THICK LAYER DOPED WITH METAL AMIDES FOR USE AS HOLE INJECTION LAYER FOR AN ORGANIC LIGHT-EMITTING DIODE (OLED) | Novaled GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | NPY5R, NPY1R, NPY4R | CA1 4750/4885CA2 4173/4885CA9 4329/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | CA1 2080/4885CA2 2597/4885CA9 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.